The gurus of Radha Soami Satsang Beas (RSSB) are supposed to demonstrate exceptionally high spiritual virtues, including honesty. After all, the RSSB teachings proclaim that their gurus are God in Human Form.
So a few days ago, when I saw on the RSSB web site that Gurinder Singh Dhillon, the organization's current guru, had appointed a successor, Jasdeep Singh Gill, I was surprised to see that Gill had worked at Ranbaxy from 2006 to 2010.
Ranbaxy (2006 – 2010): Multiple roles
Worked across Project management and Strategy functions
Surprised, because Ranbaxy was accused of pharmaceutical fraud following sale of the company to Daiichi Sankyo in 2008, following which the fraud allegations came to light.
In 2013 the U.S. Department of Justice announced that Ranbaxy had agreed to plead guilty to several felonies.
In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty today to felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy’s manufacturing facilities in India, the Justice Department announced today. Ranbaxy also agreed to pay a criminal fine and forfeiture totaling $150 million and to settle civil claims under the False Claims Act and related State laws for $350 million.
And when did the illegal manufacture and distribution of adulterated drugs take place at the two Ranbaxy manufacturing facilities in India? At the same time (2006-10) Jasdeep Gill was serving as Executive Assistant to the CEO of Ranbaxy, Malvinder Singh. That's an important position. We have to assume that Malvinder was the one who hired Jasdeep.
The Department of Justice announcement says:
Ranbaxy USA admitted to introducing into interstate commerce certain batches of adulterated drugs that were produced at Paonta Sahib in 2005 and 2006, including Sotret, gabapentin, and ciprofloxacin... Ranbaxy also acknowledged that the FDA’s 2006 and 2008 inspections of the Dewas facility found the same issues with incomplete testing records and an inadequate stability program, as well as significant cGMP deviations in the manufacture of certain active pharmaceutical ingredients and finished products.
There's more, so bear with me on what admittedly is fairly complex corporate malfeasance. I've shared additional detail in previous blog posts for those who really want to learn about the Ranbaxy-related scandals.
First, Gurinder Singh, the current RSSB guru, reportedly was highly involved in Ranbaxy dealings. In 2016 a Singapore tribunal awarded Daiichi Sankyo about $500 million in damages because Ranbaxy hadn't divulged its pharmaceutical quality problems in the course of the sale to Daiichi Sankyo.
Then, according to the preceding link, "In 2018, Daiichi Sankyo approached the Indian Supreme Court with the allegation that the Singh brothers were diverting funds using a number of shell companies to avoid the payments."
Now Gurinder Singh enters the picture again. Because Malvinder Singh accused the RSSB guru in a criminal lawsuit of being a recipient of that massive money diversion via shell companies. Religare and Fortis were companies once owned by Malvinder and Shivinder Singh into which they pumped much of the $2 billion received from the sale of Ranbaxy.
In 2019, the Serious Fraud Investigation Office, or SFIO, was also probing their [Singh brothers] role in an alleged fund diversion at Fortis Healthcare. After its initial probe, the SFIO had said that it believed that the fraud could be to the tune of Rs 2,000 crore. The Securities and Exchange Board of India and the SFIO suspected that the Singh brothers had diverted public money from Fortis Healthcare to Gurinder Singh Dhillon, the head of Radha Soami Satsang Beas and other religious bodies.
In 2019 Gurinder Singh, his family, and close associates were ordered by the High Court of Delhi to pay hundreds of millions of dollars to RHC Holding so the money that was siphoned off into their pockets could be used to pay what Malvinder and Shivinder Singh owed Daiichi Sankyo.
NEW DELHI: Gurinder Singh Dhillon, the spiritual head of the Radha Soami Satsang Beas (RSSB), his family members and associates are among 55 individuals and entities ordered by a court to pay over Rs 6,000 crore owed to RHC Holding in connection with the settlement of a dispute related to Daiichi Sankyo’s acquisition of Ranbaxy Laboratories.
The Delhi high court ordered Dhillonʼs wife Shabnam, sons Gurkirat and Gurpreet and daughter-in-law Nayan Tara, among others, to pay up the amount due to RHC Holding, the flagship holding company of the Singh brothers who formerly owned Ranbaxy. Money will also be recovered from former Religare Enterprises chief Sunil Godhwani and his brother Sanjay Godhwani. The non-banking financial services conglomerate was formerly promoted by Malvinder and Shivinder Singh.
So Jasdeep Singh was part of the financial scandals that started with the illegal actions by Ranbaxy regarding dangerously adulterated pharmaceuticals at a time when Gurinder Singh's nephew, Malvinder Singh, was CEO of Ranbaxy and Jasdeep Singh was an executive assistant to Malvinder.
In my post, "'Dirty money' tied to RSSB guru's Ranbaxy wealth," I quoted from a Wikipedia article about Malvinder Singh and Ranbaxy.
Malvinder Singh's tenure as CEO of Ranbaxy starting in 2006 is controversial. Corporate culture of fraud continued unchecked under his tenure.
Jasdeep Singh, the guru-in-waiting of Radha Soami Satsang Beas, the hand-chosen successor to Gurinder Singh, became the executive assistant to Malvinder Singh in 2006. It's difficult to imagine that someone so close to the Ranbaxy CEO, who almost certainly was hired by Malvinder, wasn't aware of that "corporate culture of fraud" during the four years he worked at Ranbaxy.
Jasdeep Singh Gill should be questioned about this by the Indian financial press. He's a distant cousin of Gurinder Singh Dhillon. Malvinder Singh also is related to Gurinder Singh, a nephew I believe, though genealogy isn't my strong suit. Here's a Family Tree that someone sent to me today. The Gill and Dhillon families are linked.
Given how closely Gurinder Singh was involved with Ranbaxy and the Singh brothers at the time, it seems entirely possible that the RSSB guru had a say in the hiring of Jasdeep by Malvinder. You know, keep everything in the family.
Now Gurinder has chosen Jasdeep as his successor, also keeping the RSSB guru'dom in the family. It's unsure why this happened now. RSSB says that the guru's health is fine. If that's true, then it's possible that the guru's legal problems played a role in his decision to step aside from managing the large RSSB financial and real estate holdings, handing that over to Jasdeep as of a few days ago.
I give credit for stimulating this post to a Church of the Churchless reader who emailed me with thoughts about Jasdeep Singh Gill's connection with Ranbaxy. This person had read Bottle of Lies, a book about the fraud in the generic drug industry. An excerpt from the book about Ranbaxy was shared with me:
At the behest of managers, the scientists substituted lower-purity ingredients for higher ones to reduce costs. They altered test parameters so that formulations with higher impurities could be approved. They faked dissolution studies.
For some markets, the company fraudulently mixed and matched data streams, taking the best data from manufacturing in one market and presenting it to regulators elsewhere as data unique to the drugs in their markets. For other markets, the company simply invented data. Document forgery was pervasive.
The company even forged its own standard operating procedures, which FDA investigators rely on to assess whether a company is following its own policies.
In one instance, employees backdated documents and then artificially aged them in a steamy room overnight in an attempt to fool regulators during inspections.
There was little effort to conceal this method of doing business. It was common knowledge, from senior managers and heads of research and development to people responsible for formulation and the clinical people. Essentially, Ranbaxy's manufacturing standards boiled down to whatever the company could get away with.'
This person commented:
What am trying to get at is that if it was common knowledge all this was taking place, plus the using of brand name drugs crushed up and made into capsules to be tested plus superimposing brand-name test results onto their own applications, unless everyone was briefed to change tactics, there is no way Gill couldn't have known.
Here's more of what this person wrote to me. The quote at the beginning is from an unnamed source. It seems accurate.
Malvinder and Shivinder Singh were running Ranbaxy until 2008 when they sold their stake.
"11 June 2008, Malvinder Singh stunned the Indian business world by announcing that he and his brother were selling their 33.5% stake in Ranbaxy to the Japanese drugmaker Daiichi Sankyo for $2 billion."
'Stunned' the business world because Ranbaxy was at its peak. Malvinder and Shivinder were arrested in October 2019.
So Gill was there during the rampant fraud going on and Ranbaxy had Malvinder as CEO. Gill must have been aware something was wrong?
Thakur, the main whistleblower knew there was something seriously wrong in 2003. Thakur encountered chaos. Disputes at executive meetings sometimes escalated into fistfights. He said, "There was no structure. It was the complete antithesis of everything I had learned for ten or twelve years."
Everyone tried to block every single attempt he introduced to sort the mess out. His boss who had employed him resigned because of the rampant corruption. He told Thakur he knew enough to bring the company down.
I have to condense this. Brian.
His next boss had the same problem. He discovered there was astonishing fraud going on. Astonishing is the right word! Ranbaxy was lying about everything. The drugs destined for terribly sick AIDS patients had not even been tested.
When Thakur's boss 2 told the corporate office the drugs must be immediately withdrawn, they refused. Thakur's boss responded by telling them he was a physician and no way was he going to sign off something he knew full well was going to cause harm to patients. Either they pull the stuff off the market or he was resigning.
Anyway, Ranbaxy was faking its dossiers to the FDA, Europe and India. At behest of the managers of Ranbaxy, (Malvinder and Shivinder) scientists substituted lower purity ingredients for higher ones to reduce cost. They faked everything. To generate normal results, they crushed up brand name drugs into capsules so that they could be tested instead of Ranbaxy's own drugs. They then used the brand-name results as their own.
It goes on an on. In markets including Brazil, Kenya, Ethiopia, Uganda, Egypt, Myanmar, Thailand, Vietnam, Peru, and Dominican Republic, Ranbaxy simply invented all the data. Thakur's boss 2 resigned when they refused to withdraw the crap drugs and stop selling them to all these countries.
Then they got rid of Thakur because they knew he knew too much. After they combed his computer for incriminating evidence against Ranbaxy they hacked his servers and planted his IP address on porn sites.
Thakur was furious and handed in his resignation providing the evidence of computer tampering. Thakur then decided to contact the FDA and present his evidence....long story.....
Will leave it there, Brian because it's a long, convoluted saga but just to give you a preliminary background sketch.
I can't believe Gill was not aware of what was going on. He was there when Malvinder and Shivinder were at the helm for four whole years until they sold their stake to the Japanese company when they were being asked to present legal data to UNICEF which they couldn't do. Neither could they supply data to the FDA.....am being vèry brief.
And who got Gill the job? More nepotism? Gill is Babaji's [Gurinder Singh's] mother's sister's grandson. They are related. Yikes!
Recent Comments